[Targeted radionuclide therapy for castration-resistant prostate cancer]

Katsumasa Nakamura, Ohga Saiji, Tomonari Sasaki, Shingo Baba, Hiroshi Honda

研究成果: Contribution to journalReview article査読

抄録

Although patients with castration-resistant prostate cancer frequently have metastases to the bone, they have a relatively favorable prognosis. Therefore, it is important to keep or improve the level of patient's quality of life. The use of strontium-89 for the management of the pain from bone metastasis was approved in 2007 in Japan. A new bone-targeting radiopharmaceuticals using radium-223 is also promising, because a randomized trial showed an overall survival advantage of radium-223 in prostate patients with bone metastases. In this review, we summarize the role of targeted radionuclide therapy for castration-resistant prostate cancer, focusing on strontium-89 and radium-223.

本文言語英語
ページ(範囲)2181-2185
ページ数5
ジャーナルNihon rinsho. Japanese journal of clinical medicine
72
12
出版ステータス出版済み - 12 1 2014

All Science Journal Classification (ASJC) codes

  • Medicine(all)

フィンガープリント 「[Targeted radionuclide therapy for castration-resistant prostate cancer]」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル